USFDAAug 12, 2026, 04:09 PM
Outlook Therapeutics' LYTENAVA Gets US FDA Approval
AI Summary
Outlook Therapeutics announced that its drug LYTENAVA™ (bevacizumab-vikg) received U.S. FDA approval for neovascular age-related macular degeneration (nAMD) on July 24, 2026. The company reported preliminary cash and cash equivalents of approximately $11.2 million as of June 30, 2026, and terminated its prospectus supplement for an At The Market Offering Agreement. Outlook Therapeutics also disclosed substantial doubt about its ability to continue as a going concern, emphasizing the need for significant additional capital to fund LYTENAVA's commercialization, as current funds are only sufficient into September 2026.
Key Highlights
- LYTENAVA™ (bevacizumab-vikg) received US FDA approval for wet AMD.
- Preliminary cash and cash equivalents were approximately $11.2 million as of June 30, 2026.
- Terminated prospectus supplement for At The Market Offering Agreement with H.C. Wainwright.
- Company faces substantial doubt about its ability to continue as a going concern.
- Requires substantial additional capital to fund LYTENAVA commercialization.
- Cash and equivalents are sufficient only into September 2026.
- $19.8 million outstanding on March 2026 Note to Atlas Sciences LLC.
- Fiscal year 2025 revenue from LYTENAVA sales was $1.4 million.
Price Impact
More from OTLK